Table 1.
Correlation between PCAT14 and clinical indicators of patients.
| Low expression of PCAT14 | High expression of PCAT14 | P | |
|---|---|---|---|
| n | 249 | 250 | |
| T stage, n (%) | 0.005 | ||
| T2 | 76 (15.4%) | 113 (23%) | |
| T3 | 160 (32.5%) | 132 (26.8%) | |
| T4 | 7 (1.4%) | 4 (0.8%) | |
| N stage, n (%) | 0.009 | ||
| N0 | 169 (39.7%) | 178 (41.8%) | |
| N1 | 52 (12.2%) | 27 (6.3%) | |
| M stage, n (%) | 0.249 | ||
| M0 | 230 (50.2%) | 225 (49.1%) | |
| M1 | 3 (0.7%) | 0 (0%) | |
| Primary therapy outcome, n (%) | 0.022 | ||
| PD | 16 (3.7%) | 12 (2.7%) | |
| SD | 18 (4.1%) | 11 (2.5%) | |
| PR | 27 (6.2%) | 13 (3%) | |
| CR | 156 (35.6%) | 185 (42.2%) | |
| Race, n (%) | 0.195 | ||
| Asian | 9 (1.9%) | 3 (0.6%) | |
| Black or African American | 30 (6.2%) | 27 (5.6%) | |
| White | 204 (42.1%) | 211 (43.6%) | |
| Age, n (%) | 0.342 | ||
| ≤60 | 106 (21.2%) | 118 (23.6%) | |
| >60 | 143 (28.7%) | 132 (26.5%) | |
| Residual tumor, n (%) | <0.001 | ||
| R0 | 133 (28.4%) | 182 (38.9%) | |
| R1 | 100 (21.4%) | 48 (10.3%) | |
| R2 | 1 (0.2%) | 4 (0.9%) | |
| PSA (ng/ml), n (%) | 0.347 | ||
| <4 | 199 (45%) | 216 (48.9%) | |
| ≥4 | 16 (3.6%) | 11 (2.5%) | |
| Gleason score, n (%) | < 0.001 | ||
| 6 | 16 (3.2%) | 30 (6%) | |
| 7 | 103 (20.6%) | 144 (28.9%) | |
| 8 | 34 (6.8%) | 30 (6%) | |
| 9 | 92 (18.4%) | 46 (9.2%) | |
| 10 | 4 (0.8%) | 0 (0%) | |
| OS event, n (%) | 0.339 | ||
| Alive | 246 (49.3%) | 243 (48.7%) | |
| Dead | 3 (0.6%) | 7 (1.4%) | |
| Age, mean ± SD | 61.74 ± 6.48 | 60.32 ± 7.08 | 0.020 |
| PSA (ng/ml), mean ± SD | 2.79 ± 22.41 | 0.76 ± 3.34 | 0.179 |
PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response; PSA: prostate-specific antigen; OS: overall survival.